Batgi Hikmetullah, Akbal Erdem, Koçak Erdem, Akyürek Ömer, Köklü Seyfettin, Dönmez Melahat, Güneş Fahri
Deparment of Internal Medicine, Ankara Education and Research Hospital, Ankara, Turkey.
Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
Wien Klin Wochenschr. 2016 Dec;128(Suppl 8):559-565. doi: 10.1007/s00508-015-0762-2. Epub 2015 Apr 10.
Ankaferd blood stopper (ABS) is a herbal extract that enhances mucosal healing. It has therapeutic potential in the management of external hemorrhage and controlling gastrointestinal bleeding associated with various benign lesions refractory to conventional antihemorrhagic measures. The aim of this experimental study was to assess the effects of ABS on hemorrhagic lesions and compare them with omeprazole.
The study was conducted on 30 rats. Rats were divided into five groups: group A (only indomethacin), group B (ABS administration 60 min before indomethacin-induced injury), group C (ABS administration 30 min after indomethacin-induced injury), group D (omeprazole administration 60 min before indomethacin-induced injury), group E (omeprazole administration 30 min after indomethacin-induced injury). Gastric mucosal lesions were produced by indomethacin in all three groups. The effect was studied morphologically 6 h after oral administration of the drug. Subsequently, affected tissue was examined histologically.
Based on the number and the total size of hemorrhagic lesions, the hemorrhagic lesion scores were significantly better in Group C compared to other groups (p < 0.05). The hemorrhagic lesion score of Group B was significantly better than Group D and Group A (p < 0.05). Omeprazole groups (Group D, Group E) did not show significant improvement as indicated by macroscopic scores. There was no significant difference between the groups with respect to microscopic scores.
These results indicate that ABS has a potent inhibitory action on indomethacin-induced gastric bleeding and mucosal lesions and it is useful in the treatment of acute gastric mucosal lesions.
安卡非德止血剂（ABS）是一种能促进黏膜愈合的草药提取物。它在治疗外出血以及控制与各种常规止血措施难以奏效的良性病变相关的胃肠道出血方面具有治疗潜力。本实验研究的目的是评估ABS对出血性病变的影响，并将其与奥美拉唑进行比较。
该研究以30只大鼠为对象。大鼠被分为五组：A组（仅给予吲哚美辛），B组（在吲哚美辛诱导损伤前60分钟给予ABS），C组（在吲哚美辛诱导损伤后30分钟给予ABS），D组（在吲哚美辛诱导损伤前60分钟给予奥美拉唑），E组（在吲哚美辛诱导损伤后30分钟给予奥美拉唑）。所有三组均通过吲哚美辛造成胃黏膜损伤。在口服药物6小时后从形态学上研究其效果。随后，对受影响的组织进行组织学检查。
基于出血性病变的数量和总面积，C组的出血性病变评分显著优于其他组（p < 0.05）。B组的出血性病变评分显著优于D组和A组（p < 0.05）。如宏观评分所示，奥美拉唑组（D组、E组）未显示出显著改善。各组织学评分组间无显著差异。
这些结果表明，ABS对吲哚美辛诱导的胃出血和黏膜损伤具有强效抑制作用，并且对急性胃黏膜损伤的治疗有效。
